B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

EPHA7

MOLECULAR TARGET

EPH receptor A7

UniProt: Q15375NCBI Gene: 204526 compounds

EPHA7 (EPH receptor A7) is targeted by 26 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting EPHA7

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1erlotinib5.55256
2foretinib4.3476
3vandetanib4.3073
4doramapimod4.0657
5quizartinib3.9953
6canertinib3.5333
7tae 6843.4330
8fedratinib3.4029
9gilteritinib3.4029
10linifanib3.3327
11mln 80543.3327
12jnj 77066213.0921
13at 92833.0921
14lestaurtinib3.0420
15danusertib2.9418
16r 4062.8316
17cediranib2.8316
18kw 24492.6413
19ast 4872.5612
20brivanib2.4811
21bms 7548072.309
22su 0148132.208
23rebastinib2.208
24golvatinib2.208
25Sorafenib1.795
26Crizotinib0.691

About EPHA7 as a Drug Target

EPHA7 (EPH receptor A7) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 26 compounds with documented EPHA7 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

EPHA7 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.